bioRxiv Science⌕ Search

Biology subjects

Yeo, L.

Publications and source records attributed to Yeo, L..

2 recordsLinked to original sources

Sonoepigenetics: Spatiotemporal Calcium Dynamics and cAMP Signaling Driven by High Frequency Nanomechanostimulation Regulates Transient Epigenetic Modifications and Early Osteogenic Commitment in Mesenchymal Stem Cells

Cells effectively balance and integrate numerous pathways to adapt to external signals in an attempt to regain homeostasis, although the complex nuclear mechanotransduction mechanism through which this occurs is not as yet fully understood. Contrary to prevalent thought that the relay of extracellular cues to the nucleus to effect its fate and function predominantly relies on direct transmission through the cytoskeletal structure, we demonstrate, through the use of high frequency (10 MHz) nanomechanostimulation, that induced fluctuations of the cells nuclear chromatin response are primarily influenced by the spatiotemporal dynamics associated with the bidirectional crosstalk between two key second messengers, namely calcium (Ca2+) and cyclic adenosine monophosphate (cAMP). We show that this conditioning is an adaptive response to the mechanostimuli and correlates with a mechanopriming effect. Notably, brief (10 mins) daily exposure to the mechanostimulation was sufficient to direct mesenchymal stem cells toward an osteogenic lineage in as little as three days--without the need for osteogenic factors.

cell biology↗

The Antagonism of Folate Receptor by the Integrase Inhibitor Dolutegravir

Human immunodeficiency virus (HIV) integrase inhibitors are increasingly being used for antiretroviral therapy (ART), and dolutegravir (DTG/Tivicay) has emerged as a leading core agent. In 2018, the Tsepamo study reported a 6- to 9-fold increase for neural tube defect (NTD) risk among the offspring of mothers receiving DTG during early gestation. Maternal folate (vitamin B9) status is the largest known modifier of NTD risk, so we evaluated folate-related mechanisms of action and the critical period for DTG developmental toxicity. Folate receptor (FOLR1) binding studies indicate DTG is a non-competitive FOLR1 antagonist at therapeutic concentrations. In vitro testing indicates calcium (2mM) increases FOLR1-folate interactions and alters DTG-FOLR1-folate interactions and cytotoxicity. DTG does not inhibit downstream folate metabolism by dihydrofolate reductase (DHFR). Early embryonic exposure to DTG is developmentally toxic in zebrafish, and supplemental folic acid can mitigate DTG developmental toxicity. The results from these studies are expected to inform and guide future animal models and clinical studies of DTG-based ART in women of childbearing age.

pharmacology and toxicology↗